Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Excellent News - GSK progressing ultimately towards delivering positive outcomes to controlling multi variant virus worldwide.
'Results from the Phase 3 study are expected in the first half of 2022 after which, subject to positive results and regulatory approval, the vaccine is expected to be supplied at scale worldwide through the COVAX facility'.
Reply to Denby 69 STAY POSITIVE
...Or may buck the trend and go up; interesting news from US
overnight:
"AnaptysBio Inc. shares rose 10% to $27.72 after hours as a second approved indication for a GlaxoSmithKline PLC drug will result in a $20 million milestone payment. The U.S. Food and Drug Administration approved GSK's Jemperli for the treatment of adult patients with mismatch repair deficient recurrent or advanced solid tumors. Jemperli was generated by AnaptysBio and subsequently developed by Tesaro Inc., which GSK bought in early 2019.
GlaxoSmithKline PLC - Brentford, Middlesex-based pharmaceutical firm - GSK and Vir Biotechnology Inc say the European Medicines Agency has started a rolling review of test results for their Covid-19 treatment sotrovimab. The review is for use in people 12 years and older. A rolling review means the EMA will evaluate the test data on sotrovimab as it becomes available. A formal marketing authorisation application will be made once there is enough supporting evidence. Sotrovimab has not yet been granted marketing authorisation anywhere in the world, though an Emergency Use Authorization application has been submitted to the US Food & Drug Administration.
Current stock price: 1,350.80 pence
Year-to-date change: up 0.7%
By Tom Waite; thomaslwaite@alliancenews.com